Phase 3 Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are 18 years of age or older at the time of signing the consent form
• People who have been diagnosed with a specific type of acute myeloid leukemia (a blood cancer) that has not yet been treated, involving particular gene changes (called KMT2Ar or NPM1m), with at least 10% abnormal cells found in the bone marrow
• People who have been assessed by their doctor as not suitable for intensive (strong) chemotherapy — this applies to people aged 75 or older based on their doctor's judgment, or people aged 18 to under 75 who have at least one serious health condition such as reduced physical ability, a severe heart condition, a severe lung condition, kidney problems, moderate liver problems, or another condition the treating doctor considers makes intensive chemotherapy unsuitable (confirm with trial site for full details on how this is assessed)
• People whose liver and kidney are functioning at an adequate level as determined by the trial team
• Female participants who agree not to be pregnant or breastfeed, not to plan a pregnancy, and to use specific birth control methods during the trial and for 6 months after the last dose of study treatment
• Male participants who agree to use specific birth control methods during the trial and for at least 90 days after the last dose of study treatment
• People who have read and signed a consent form showing they understand and are willing to take part in the study

Who may not be able to join:

• People diagnosed with a specific subtype of blood cancer called acute promyelocytic leukemia (APL)
• People with active leukemia that has spread to the brain or spinal cord
• People who have previously received a solid organ transplant (such as a kidney, liver, or heart transplant)
• People who have experienced certain heart-related events within the 6 months before joining, including a heart attack, uncontrolled chest pain, heart failure, uncontrolled or symptomatic irregular heartbeat, a blocked blood vessel to the brain, or a mini-stroke
• People with a currently active hepatitis infection affecting the liver
• People who have received a live vaccine within 4 weeks before joining the trial
• People with known allergies or sensitivities to the study medications (bleximenib, azacitidine, or venetoclax) or their ingredients

Important: Always verify eligibility with the trial site directly before applying.